Biological Domain Classification System
Critical Analysis of v1.0 (12 Domains)
Issues with Current Classification
Issues with Current Classification
Structural Problems
| Issue | Description | Examples |
|---|---|---|
| Inconsistent granularity | Mixing very specific systems with very broad categories | Cholinergic (specific neurotransmitter) vs. Neuroprotection (broad outcome) |
| Missing major neurotransmitter | Glutamate is the brain’s PRIMARY excitatory neurotransmitter | Glycine is an NMDA co-agonist; Mg is NMDA modulator — where do they map? |
| Noradrenergic omission | Norepinephrine is distinct from dopamine with different functions | Tyrosine → L-DOPA → Dopamine → Norepinephrine — this pathway is incomplete |
| Redundant energy domains | Mitochondrial, ATP Systems, NAD+ Metabolism overlap significantly | All are “cellular energy” — unclear boundaries |
| Missing vascular domain | No place for L-Citrulline, NO, blood flow | A core Neuraldrink™ mechanism has no domain |
| Missing immune/inflammatory | Omega-3s, adaptogens affect inflammation | No domain for this major pathway |
| Outcome vs. mechanism confusion | ”Neuroprotection” is an outcome, not a biological system | BDNF, NGF, antioxidants are mechanisms; “protection” is the result |
Missing Domains (Critical)
| Omitted Domain | Why It Matters | NTRPX Ingredients That Target It |
|---|---|---|
| Glutamatergic/NMDA | Primary excitatory neurotransmitter; glycine’s sleep mechanism works via NMDA | Glycine, Magnesium, Theanine |
| Noradrenergic | Alertness, attention, stress response; distinct from dopamine | Tyrosine, Caffeine, Paraxanthine |
| Vascular/Nitric Oxide | Blood flow to brain and body; endothelial function | L-Citrulline, DHA/EPA |
| Immune/Inflammatory | Cytokine modulation, inflammation control | Omega-3s, Ashwagandha, Cordyceps |
| Glucose Metabolism | Brain’s primary fuel; insulin sensitivity | Chromium, B-vitamins, Glucose itself |
Boundary Ambiguities
| Ingredient | Current Assignment Problem |
|---|---|
| Glycine | Assigned to “Circadian” but mechanism is NMDA → hypothalamic thermoregulation |
| L-Theanine | Assigned to “GABAergic” but also modulates glutamate |
| Magnesium | Affects GABA, NMDA, ATP, HPA — where does it primarily belong? |
| Omega-3s | Assigned to “Structural” but also anti-inflammatory and neuroprotective |
| Creatine | Is it “ATP Systems” or “Mitochondrial”? |
Proposed Domain Classification v2.0
Design Principles
- Mechanistic, not outcome-based — Domains describe biological pathways, not desired results
- Consistent granularity — All domains at similar level of specificity
- Mutually exclusive, collectively exhaustive (MECE) — Minimal overlap, complete coverage
- Supplement-relevant — Domains map to ingredients we can actually modulate
- Hierarchically organized — Related domains grouped into super-categories
The 16-Domain Classification System
Domain Definitions & Key Markers
I. NEUROTRANSMISSION (Domains 1-5)
I. NEUROTRANSMISSION (Domains 1-5)
Domain 1: Cholinergic System
Definition: Acetylcholine synthesis, release, receptor activation, and degradation pathways.| Aspect | Details |
|---|---|
| Primary neurotransmitter | Acetylcholine (ACh) |
| Key enzymes | Choline acetyltransferase (ChAT), Acetylcholinesterase (AChE) |
| Receptors | Nicotinic (nAChR), Muscarinic (mAChR) |
| Functions | Memory encoding, sustained attention, learning, neuromuscular junction |
| NTRPX ingredients | CDP-Choline, Alpha-GPC, Huperzine A, Phosphatidylserine |
| Biomarkers | RBC AChE activity, choline levels |
Domain 2: Catecholaminergic System
Definition: Dopamine AND norepinephrine/epinephrine synthesis, release, reuptake, and degradation. Combined because they share a biosynthetic pathway.| Aspect | Dopaminergic | Noradrenergic |
|---|---|---|
| Functions | Motivation, reward, executive function | Alertness, attention, stress response |
| Receptors | D1-D5 | α1, α2, β1, β2, β3 |
| Degradation | MAO-A/B, COMT | MAO-A, COMT |
| NTRPX ingredients | Tyrosine, Mucuna (L-DOPA), Salidroside (MAO-B) | Tyrosine, Caffeine, Paraxanthine |
Domain 3: Serotonergic System
Definition: Serotonin (5-HT) synthesis, release, reuptake, and receptor modulation.| Aspect | Details |
|---|---|
| Primary neurotransmitter | Serotonin (5-hydroxytryptamine, 5-HT) |
| Biosynthesis | Tryptophan → 5-HTP → Serotonin |
| Receptors | 5-HT1A through 5-HT7 (14+ subtypes) |
| Functions | Mood regulation, emotional well-being, gut motility, sleep onset |
| NTRPX ingredients | Saffron (reuptake), Bacopa (5-HT modulation) |
| Note | 95% of serotonin is in gut; CNS serotonin is synthesized locally |
Domain 4: GABAergic System
Definition: Gamma-aminobutyric acid synthesis, receptor modulation, and inhibitory tone.| Aspect | Details |
|---|---|
| Primary neurotransmitter | GABA (gamma-aminobutyric acid) |
| Biosynthesis | Glutamate → GABA (via GAD; requires P5P) |
| Receptors | GABA-A (ionotropic, fast), GABA-B (metabotropic, slow) |
| Binding sites | GABA site, Benzodiazepine site, Barbiturate site, Neurosteroid site |
| Functions | Inhibitory tone, anxiety reduction, sleep, muscle relaxation |
| NTRPX ingredients | L-Theanine, Taurine, Apigenin, Magnesium, Ashwagandha |
Domain 5: Glutamatergic System (NEW)
Definition: Glutamate signaling, NMDA/AMPA receptor modulation, and excitatory-inhibitory balance.| Aspect | Details |
|---|---|
| Primary neurotransmitter | Glutamate (THE primary excitatory NT) |
| Key receptors | NMDA, AMPA, Kainate (ionotropic); mGluR (metabotropic) |
| NMDA requirements | Glutamate + Glycine (co-agonist) + Depolarization + Mg²⁺ unblock |
| Functions | Learning, memory consolidation, synaptic plasticity, LTP |
| NTRPX ingredients | Glycine (NMDA co-agonist), Magnesium (voltage-dependent block), L-Theanine (glutamate modulation) |
II. ENERGY METABOLISM (Domains 6-9)
II. ENERGY METABOLISM (Domains 6-9)
Domain 6: Mitochondrial System
Definition: Mitochondrial biogenesis, dynamics (fusion/fission), and oxidative phosphorylation efficiency.| Aspect | Details |
|---|---|
| Biogenesis pathway | PGC-1α → NRF1/2 → TFAM → mtDNA transcription |
| Key activators | AMPK, SIRT1, CREB |
| Electron transport chain | Complex I-IV + ATP synthase |
| NTRPX ingredients | PQQ (biogenesis), CoQ10 (ETC), Cordyceps (O₂ utilization) |
| Biomarkers | Mitochondrial DNA copy number, citrate synthase activity |
Domain 7: Bioenergetics (ATP/Phosphocreatine)
Definition: Immediate and short-term energy buffering systems; ATP regeneration.| System | Timeframe | NTRPX Ingredients |
|---|---|---|
| Phosphocreatine (PCr) | 0-10 seconds | Creatine |
| Glycolytic | 10 sec - 2 min | Glucose, B-vitamins (cofactors) |
| Oxidative | >2 min | Mitochondrial support |
Domain 8: NAD+ Metabolism
Definition: Nicotinamide adenine dinucleotide synthesis, consumption, and salvage pathways.| NTRPX Ingredients | Mechanism |
|---|---|
| NR (Niagen®) | NAD+ precursor (salvage pathway) |
| Apigenin | CD38 inhibitor (preserves NAD+) |
| Niacinamide | Direct NAD+ precursor |
Domain 9: Glucose Metabolism (NEW)
Definition: Glucose uptake, glycolysis, gluconeogenesis, and insulin signaling.| Aspect | Details |
|---|---|
| Brain requirement | ~120g glucose/day; 20-25% of body’s total |
| Key transporters | GLUT1 (BBB), GLUT3 (neurons), GLUT4 (insulin-responsive) |
| Glycolysis cofactors | Thiamine (B1), Riboflavin (B2), Niacin (B3), Pantothenic acid (B5), Magnesium |
| Insulin sensitivity | Chromium, Magnesium |
| NTRPX ingredients | D-Glucose, Chromium, B-vitamins, Magnesium |
III. CELLULAR PROCESSES (Domains 10-12)
III. CELLULAR PROCESSES (Domains 10-12)
Domain 10: Methylation / Epigenetic
Definition: One-carbon metabolism, methylation reactions, and epigenetic regulation.| Aspect | Details |
|---|---|
| Universal methyl donor | S-adenosylmethionine (SAMe) |
| 200+ reactions | DNA methylation, neurotransmitter synthesis, creatine synthesis, phospholipid synthesis |
| Key variants | MTHFR C677T (30%+ population) |
| NTRPX ingredients | L-5-MTHF, Methylcobalamin, Adenosylcobalamin, P5P, R5P |
Domain 11: Membrane & Structural Integrity
Definition: Phospholipid composition, membrane fluidity, and structural support.| Component | Function | NTRPX Ingredients |
|---|---|---|
| Phosphatidylcholine | Primary membrane phospholipid | CDP-Choline (provides choline + uridine) |
| Phosphatidylserine | Inner leaflet; signaling | Phosphatidylserine |
| DHA | Neuronal membrane fluidity; 50%+ of brain PUFA | DHA (algal) |
| EPA | Anti-inflammatory; membrane precursor | EPA (algal) |
| Cholesterol | Membrane structure; myelin | (Endogenous) |
Domain 12: Cellular Homeostasis (Autophagy & Repair)
Definition: Protein quality control, autophagy, DNA repair, and cellular maintenance.| Process | Description | Modulators |
|---|---|---|
| Autophagy | ”Self-eating” — degradation of damaged components | AMPK activation, mTOR inhibition |
| Mitophagy | Selective autophagy of damaged mitochondria | PINK1/Parkin pathway |
| DNA repair | Base excision, nucleotide excision, double-strand break repair | NAD+ (PARP substrate), Zinc |
| Proteostasis | Protein folding, chaperones, proteasome | Heat shock proteins |
| NTRPX ingredients | NR (NAD+ for PARP), Zinc, Apigenin (autophagy modulation) |
IV. REGULATORY SYSTEMS (Domains 13-14)
IV. REGULATORY SYSTEMS (Domains 13-14)
Domain 13: HPA Axis & Stress Response
Definition: Hypothalamic-pituitary-adrenal axis function, cortisol regulation, and stress adaptation.| Aspect | Details |
|---|---|
| Key hormones | CRH, ACTH, Cortisol |
| Diurnal rhythm | Cortisol peaks AM, lowest at midnight |
| Adaptogen mechanisms | HSP70 induction, cortisol modulation, neurotransmitter balance |
| NTRPX ingredients | Ashwagandha, Rhodiola/Salidroside, Phosphatidylserine, Cordyceps |
Domain 14: Circadian & Sleep Architecture
Definition: Sleep-wake cycle regulation, melatonin signaling, and core body temperature rhythm.| Process | Mechanism | NTRPX Ingredients |
|---|---|---|
| Sleep onset | Core temp ↓, melatonin ↑ | Glycine (thermoregulation), Melatonin (0.3mg) |
| Sleep architecture | NREM/REM cycling, slow-wave sleep | Magnesium, Taurine, Apigenin |
| Clock genes | CLOCK, BMAL1, PER, CRY | Light exposure, feeding timing |
| Adenosine clearance | A2A receptor antagonism (wake-promoting) | Paraxanthine, Caffeine |
V. CARDIOVASCULAR & INFLAMMATORY (Domains 15-16)
V. CARDIOVASCULAR & INFLAMMATORY (Domains 15-16)
Domain 15: Vascular Function & Nitric Oxide (NEW)
Definition: Endothelial function, nitric oxide production, and blood flow regulation.| Aspect | Details |
|---|---|
| Key enzyme | Endothelial nitric oxide synthase (eNOS) |
| Cofactors | BH4, NADPH, FAD, FMN |
| Functions | Vasodilation, blood pressure regulation, exercise performance, cognitive blood flow |
| NTRPX ingredients | L-Citrulline, L-5-MTHF (BH4 recycling), Cordyceps |
Domain 16: Inflammatory Balance & Immune (NEW)
Definition: Pro-inflammatory vs. anti-inflammatory balance, cytokine modulation, and immune function.| Process | Pro-Inflammatory | Anti-Inflammatory |
|---|---|---|
| Cytokines | IL-1β, IL-6, TNF-α | IL-10, TGF-β |
| Lipid mediators | AA → Prostaglandins, Leukotrienes | EPA/DHA → Resolvins, Protectins |
| Pathways | NF-κB activation | Nrf2 activation |
| NTRPX ingredients | — | DHA, EPA, Ashwagandha, Cordyceps |
| Aspect | Details |
|---|---|
| Zinc | Immune cell function, wound healing |
| Omega-3s | Resolution of inflammation; specialized pro-resolving mediators |
| Adaptogens | Immunomodulatory; cytokine balance |
v2.0 Domain Coverage Matrix
Rating Scale:
- ★★★★★ = Primary target with maximum support (multiple ingredients, primary mechanism)
- ★★★★ = Strong support (1-2 dedicated ingredients)
- ★★★ = Moderate support (indirect or secondary mechanism)
- ★★ = Mild support (tertiary effect)
- ★ = Minimal support
- — = Intentionally excluded (circadian appropriateness or not relevant)
Complete Coverage Matrix (16 Domains × 7 Products)
| Domain | Boost™ | Sustain™ | Recover™ | Sol™ | Luna™ | ParaCaffeine +™ | Sprint™ |
|---|---|---|---|---|---|---|---|
| I. NEUROTRANSMISSION | |||||||
| 1. Cholinergic | ★★★★ | ★★★★ | ★ | — | — | ★★ | ★★★★★ |
| 2. Catecholaminergic | ★★★★★ | ★★ | — | ★★★ | — | ★★★★ | ★★★★★ |
| 3. Serotonergic | ★★ | ★★★★ | ★★ | — | — | — | — |
| 4. GABAergic | — | ★★ | ★★★★★ | — | ★★★★★ | — | — |
| 5. Glutamatergic | ★ | ★★ | ★★★★ | — | ★★★★ | — | — |
| II. ENERGY METABOLISM | |||||||
| 6. Mitochondrial | ★★★★★ | ★★★ | ★★★ | ★★★★ | ★★ | ★★ | ★★★ |
| 7. Bioenergetics (ATP) | ★★★★★ | ★★★★★ | ★★ | ★★★★★ | ★★ | ★★★ | ★★★★ |
| 8. NAD+ Metabolism | ★★★ | ★★ | ★★★★★ | — | ★★★ | — | ★★ |
| 9. Glucose Metabolism | ★★★★ | ★★★ | ★★ | ★★★★★ | ★★★★ | ★★ | ★★★ |
| III. CELLULAR PROCESSES | |||||||
| 10. Methylation | ★★★★★ | ★★★★ | ★★★ | ★★★ | ★★ | ★★ | ★★★ |
| 11. Membrane Integrity | ★★★ | ★★★★★ | ★★ | ★★ | ★★ | ★★ | ★★★ |
| 12. Cellular Homeostasis | ★★★ | ★★ | ★★★★★ | ★★ | ★★★★ | — | — |
| IV. REGULATORY SYSTEMS | |||||||
| 13. HPA Axis | ★★★★ | ★★★★ | ★★★ | ★★★ | ★★ | ★★ | ★★ |
| 14. Circadian | ★★★★ | ★★★ | ★★★★★ | ★★★ | ★★★★★ | ★★ | ★ |
| V. CARDIOVASCULAR | |||||||
| 15. Vascular/NO | ★★ | ★★★ | ★★ | ★★★★★ | ★★ | ★★ | ★★ |
| 16. Inflammatory Balance | ★★ | ★★★★ | ★★★ | ★★★ | ★★ | — | — |
Domain-to-Ingredient Mapping
Which Ingredients Target Which Domains?
| Ingredient | Primary Domain(s) | Secondary Domain(s) |
|---|---|---|
| CDP-Choline | 1. Cholinergic, 11. Membrane | 10. Methylation |
| Alpha-GPC | 1. Cholinergic | — |
| Huperzine A | 1. Cholinergic | — |
| L-Tyrosine | 2. Catecholaminergic | 13. HPA Axis |
| Salidroside | 2. Catecholaminergic, 13. HPA | 6. Mitochondrial |
| Mucuna (L-DOPA) | 2. Catecholaminergic | — |
| Paraxanthine | 2. Catecholaminergic, 14. Circadian | 7. Bioenergetics |
| Caffeine | 2. Catecholaminergic, 14. Circadian | 7. Bioenergetics |
| Saffron | 3. Serotonergic | — |
| Bacopa | 3. Serotonergic, 1. Cholinergic | 12. Cellular Homeostasis |
| L-Theanine | 4. GABAergic, 5. Glutamatergic | 14. Circadian |
| Taurine | 4. GABAergic | 7. Bioenergetics |
| Apigenin | 4. GABAergic, 8. NAD+ | 12. Cellular Homeostasis |
| Ashwagandha | 4. GABAergic, 13. HPA Axis | 16. Inflammatory |
| Magnesium | 4. GABAergic, 5. Glutamatergic | 7. Bioenergetics, 9. Glucose |
| Glycine | 5. Glutamatergic (NMDA co-agonist) | 14. Circadian, 10. Methylation |
| PQQ | 6. Mitochondrial (biogenesis) | — |
| CoQ10 | 6. Mitochondrial (ETC) | — |
| Cordyceps | 6. Mitochondrial, 15. Vascular | 13. HPA Axis |
| Creatine | 7. Bioenergetics | 6. Mitochondrial |
| NR (Niagen) | 8. NAD+ | 12. Cellular Homeostasis |
| B-vitamins (complex) | 9. Glucose, 10. Methylation | 6. Mitochondrial |
| Chromium | 9. Glucose | — |
| D-Glucose | 9. Glucose | 7. Bioenergetics |
| Phosphatidylserine | 11. Membrane | 13. HPA Axis |
| DHA | 11. Membrane | 16. Inflammatory |
| EPA | 11. Membrane, 16. Inflammatory | 15. Vascular |
| Lion’s Mane | 12. Cellular Homeostasis | 1. Cholinergic (NGF) |
| Zinc | 12. Cellular Homeostasis | 16. Inflammatory |
| L-Citrulline | 15. Vascular | — |
| Melatonin | 14. Circadian | — |
v1.0 → v2.0 Comparison
| Aspect | v1.0 (12 Domains) | v2.0 (16 Domains) |
|---|---|---|
| Neurotransmission | 4 domains (Cholinergic, Dopaminergic, Serotonergic, GABAergic) | 5 domains (+Glutamatergic, combined DA+NE as Catecholaminergic) |
| Energy | 3 domains (Mitochondrial, ATP, NAD+) | 4 domains (+Glucose Metabolism) |
| Cellular | 2 domains (Methylation, Cellular Repair) | 3 domains (+Membrane Integrity separated) |
| Regulatory | 2 domains (HPA, Circadian) | 2 domains (unchanged) |
| Cardiovascular | 0 domains | 2 domains (Vascular/NO, Inflammatory) |
| Neuroprotection | 1 domain (outcome-based) | Distributed across Cellular Homeostasis, Membrane, Inflammatory |
| Total | 12 | 16 |
Key Improvements
| Improvement | Rationale |
|---|---|
| Added Glutamatergic | The brain’s PRIMARY excitatory neurotransmitter was missing; glycine’s mechanism now has a home |
| Combined DA + NE | Share biosynthetic pathway; cannot be cleanly separated at intervention level |
| Added Vascular/NO | L-Citrulline, a core Neuraldrink™ ingredient, had no domain |
| Added Inflammatory | Omega-3s, adaptogens affect this critical pathway |
| Added Glucose Metabolism | Brain fuel system; central to Neuraldrink™ |
| Separated Membrane Integrity | Distinct from other cellular processes; phospholipids warrant own domain |
| Removed “Neuroprotection” | Outcome-based; mechanisms distributed to appropriate domains |
Scientific Justification Summary
MECE Design
Mutually Exclusive, Collectively Exhaustive
Each ingredient maps to specific domains without ambiguity
Mechanistic
Pathway-Based
Domains describe biological mechanisms, not desired outcomes
Supplement-Relevant
Actionable
Every domain can be modulated by nutritional intervention
Consistent Granularity
Balanced Specificity
All domains at similar level of abstraction
Document Control
| Version | Date | Author | Changes |
|---|---|---|---|
| 2.0 | 2026-01-26 | NTRPX R&D | Complete redesign with 16 scientifically-rigorous domains |

